RESUMO
Extracellular vesicles (EVs) are the common designation for ectosomes, microparticles and microvesicles serving dominant roles in intercellular communication. Both viable and dying cells release EVs to the extracellular environment for transfer of cell, immune and infectious materials. Defined morphologically as lipid bi-layered structures EVs show molecular, biochemical, distribution, and entry mechanisms similar to viruses within cells and tissues. In recent years their functional capacities have been harnessed to deliver biomolecules and drugs and immunological agents to specific cells and organs of interest or disease. Interest in EVs as putative vaccines or drug delivery vehicles are substantial. The vesicles have properties of receptors nanoassembly on their surface. EVs can interact with specific immunocytes that include antigen presenting cells (dendritic cells and other mononuclear phagocytes) to elicit immune responses or affect tissue and cellular homeostasis or disease. Due to potential advantages like biocompatibility, biodegradation and efficient immune activation, EVs have gained attraction for the development of treatment or a vaccine system against the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. In this review efforts to use EVs to contain SARS CoV-2 and affect the current viral pandemic are discussed. An emphasis is made on mesenchymal stem cell derived EVs' as a vaccine candidate delivery system.
Assuntos
Tratamento Farmacológico da COVID-19 , Sistemas de Liberação de Medicamentos/tendências , Vesículas Extracelulares , SARS-CoV-2/efeitos dos fármacos , Animais , Antivirais/administração & dosagem , Antivirais/metabolismo , COVID-19/imunologia , COVID-19/metabolismo , Sistemas de Liberação de Medicamentos/métodos , Vesículas Extracelulares/imunologia , Vesículas Extracelulares/metabolismo , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/fisiologia , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/metabolismo , SARS-CoV-2/imunologia , SARS-CoV-2/metabolismoRESUMO
The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.
